Trial Profile

Phase 1b Clinical Study of the Safety and Pharmacokinetics of Alofanib in Patients With Metastatic Gastric Cancer Resistant to Standard Therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alofanib (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Adverse reactions; First in man
Sponsors Russian Pharmaceutical Technologies

Most Recent Events

13 Mar 2023 Results investigating alofanib in heavily pretreated gastric cancer were published in the Investigational New Drugs
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
13 Apr 2022 Results assessing pharmacokinetics (PK) and results of biomarker analysis, presented at the 113th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com